药械

订阅

MedSci主页 / 所有栏目 / 药械

基因治疗成功控制乙酰氨基葡糖苷酶缺乏综合征（phase 1/2）

2015-09-20 MedSci MedSci原创

基因治疗综合征
关注

uniQure N.V. 19日宣布AMT-110治疗乙酰氨基葡糖苷酶缺乏综合征（Sanfilippo B Syndrome ）1/2期临床研究结果。NAGLU基因经AAV5载体运输至中枢神经系统成功，成功用于乙酰氨基葡糖苷酶缺乏综合征的治疗。4名患者脑脊液中NaGlu蛋白活性从0至3月后增至14-17%，持续效果至12月。4名患者年龄在20-53岁。这项研究显示，AAV5病毒载体携带基因NaGl

uniQure N.V. 19日宣布AMT-110治疗乙酰氨基葡糖苷酶缺乏综合征（Sanfilippo B Syndrome ）
1/2期临床研究结果。NAGLU基因经AAV5载体运输至中枢神经系统成功，成功用于乙酰氨基葡糖苷酶缺乏综合征的治疗。4名患者脑脊液中NaGlu蛋白活性从0至3月后增至14-17%，持续效果至12月。4名患者年龄在20-53岁。

这项研究显示，AAV5病毒载体携带基因NaGlu是安全的，而且在所有4例患者中都能稳定表达。这也是第一次使用病毒载体成功使基因治疗进入中枢，将来有望用于中枢神经系统疾病和遗传病的治疗。

同时，研究表明，该药物能够增加这些患者的认知功能。这项研究结果也在欧洲基因与细胞治疗协会（European Society of Gene and Cell Therapy (ESGCT)）大会上进行报告。


虽然，这仍然是phase 1/2研究，但是作为遗传性疾病治疗，如果进一步扩大样本，以及延长观察，仍然见到不错的疗效和安全性的话，FDA有望将来给予其孤儿药地位，加速其上市。

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2016-04-26 chentianping

    #Phase#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-10-18 hlycom3356

    这篇文章写得很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-10-18 hlycom3356

    这篇文章写得很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-10-18 hlycom3356

    这篇文章写得很好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-10-18 hlycom3356

    这篇文章写得很好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-09-22 zhouqu_8

    #综合征#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-09-21 nizongzan

    基因治疗是未来的方向，

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1788712, encodeId=83011e88712bd, content=<a href='/topic/show?id=3753141685f' target=_blank style='color:#2F92EE;'>#Phase#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14168, encryptionId=3753141685f, topicName=Phase)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Tue Apr 26 16:33:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39147, encodeId=850a3914e34, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39148, encodeId=bd053914892, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39149, encodeId=cda73914991, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39150, encodeId=8edd3915017, content=这篇文章写得很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Sun Oct 18 21:31:00 CST 2015, time=2015-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430546, encodeId=bf99143054666, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Sep 22 03:33:00 CST 2015, time=2015-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37086, encodeId=f5493e086eb, content=基因治疗是未来的方向，, beContent=null, objectType=article, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ded71629504, createdName=nizongzan, createdTime=Mon Sep 21 07:24:00 CST 2015, time=2015-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=37047, encodeId=6eb73e0471c, content=征服遗传病不是梦了啊！, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Sun Sep 20 16:59:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2015-09-20 Jin Chou

    征服遗传病不是梦了啊！

    0

相关资讯

Diabetes:抗衰老基因为糖尿病治疗带来新希望

近日，来自美国俄克拉荷马大学的华人科学家在国际学术期刊diabetes上发表了一项最新研究进展，他们发现抗衰老基因Klotho能够抑制β细胞凋亡， 而异常的细胞凋亡是造成1型糖尿病发病过程中合成胰岛素的β细胞死亡的主要原因。因此这项研究对于1型糖尿病治疗具有重要提示意义。在这项研究中，研究人员检测到最近发现的抗衰老基因Klotho基因在胰腺β细胞中也有表达。非常有趣的是，Klotho基因发生单染色

维莫斯遭遇连环打击，肾癌患者获数月生命

【新闻事件】：今天诺华制药的mTOR抑制剂依维莫斯在肾癌市场遭遇来自施贵宝和Exelixis的组合重拳打击。首先是Exelixis宣布其cMet抑制剂Cometriq（通用名cabozantinib）在一个叫做METEOR的晚期肾癌三期临床实验中达到一级终点，作为二线药物比依维莫斯显着延长无进展生存期。总生存期估计明年年初会有结果，但据中期分析显示有延长趋势。不到一小时，施贵宝宣布其PD-1抑

Cell：GWAS分析发现亨廷顿氏病潜在治疗靶基因

来自美国马萨诸塞总医院的研究人员利用GWAS分析方法对影响亨廷顿氏病发生的遗传因素进行了研究，最终发现了两个以上可以加快或延迟该疾病发生的基因突变。相关研究结果发表在国际学术期刊Cell上。

多国实施全基因组分析计划

由于基因测序可以探查与特定疾病相关的基因，该疗法正在成为日益受欢迎的诊断方法。英国计划到2017年对10万人进行基因组测序。美国加州一对龙凤胎出生后，他们的父母非常忧虑：两个婴儿不仅发育缓慢，而且肌肉松软无力。大脑扫描结果显示，男婴或存在大脑性麻痹；然而医生对造成女婴震颤和癫痫的原因却不清楚。一连串的检测均未能确诊两名婴儿的病因，当两名孩子5岁时，开始服用左旋多巴（用于治疗帕金森氏症的一种药物

ESC 2015：AAV1/SERCA2a治疗不能改善患者预后（CUPID2研究）

CUPID 2研究结果公布。该研究评估了经皮冠脉内应用基因治疗AAV1/SERCA2a（采用腺相关病毒携带SERCA2a基因的方法）对存在中到重度心力衰竭(HF)症状及射血分数降低的患者临床转归的影响，并评价其安全性。结果显示，AAV1/SERCA2a治疗不能减少复发，延长出现终末期事件的时间。这项研究结果也为心肌疾病的基因治疗打上问号。 研究纳入

诺华抗癌药Odomzo获FDA加速批准用于局部晚期基底细胞癌

瑞士制药巨头诺华（Novartis）抗癌管线近日在监管方面收获喜讯，FDA加速批准Odomzo（sonidegib，200mg）用于经手术或放射治疗后病情复发、以及不适合这2种治疗方案的局部晚期基底细胞癌（laBCC）成人患者。此前，Odomzo已于今年6月30日获瑞士批准，并于6月25日获得欧盟CHMP建议批准的积极意见。 基底细胞癌（BCC）是一种最常见的皮肤癌，约占非黑色素瘤皮肤癌的80%